Remedy Plan Therapeutics Appoints Jotin Marango, M.D., Ph.D., As New CFO & CBO To Lead Financial And Strategic Growth

Remedy Plan Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapies that target key metabolic vulnerabilities in disease, has announced the appointment of Jotin Marango, M.D., Ph.D., as its new Chief Financial and Business Officer (CFO & CBO).

Greg Crimmins, Ph.D., Founder and Chief Executive Officer of Remedy Plan Therapeutics, expressed strong confidence in the appointment. He noted that Dr. Marango brings an exceptional combination of corporate leadership, financial expertise, strategic thinking, and extensive experience in the biotechnology industry. 

According to Crimmins, as the company moves into its next phase of growth, Dr. Marango will play a vital role in strengthening the organization’s financial structure, supporting long-term strategic goals, and enhancing relationships with investors and strategic partners.

Dr. Marango joins Remedy Plan Therapeutics with more than 15 years of experience spanning biotechnology, business development, corporate strategy, and the public markets. Most recently, he served as Chief Operating Officer and Chief Financial Officer at Ikena Oncology, a company focused on designing and developing small-molecule therapies for solid tumors. 

During his time at Ikena, he played a central role in capital raising, resource allocation, and partnership development, and contributed significantly to major corporate transactions, including Ikena’s merger with ImageneBio.

Before his work at Ikena, Dr. Marango served as Chief Financial Officer and Chief Business Officer at Aptose Biosciences, supporting the early clinical development of multiple small-molecule programs for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Earlier in his career, he worked as an equity research analyst, covering small- and mid-cap biotechnology companies across hematology, oncology, and rare diseases. 

He also served as Chief Operating Officer of the Samuel Waxman Cancer Research Foundation, where he led venture philanthropy initiatives to accelerate translational drug development. Dr. Marango holds a B.A. in Chemistry with Honors from Harvard University and earned both his M.D. and Ph.D. degrees from the Mount Sinai School of Medicine of New York University.

In his statement about joining the company, Dr. Marango expressed enthusiasm about stepping into his new role at a crucial time in the company’s evolution. With Remedy Plan Therapeutics now advancing its first oncology study and pursuing a differentiated approach to NAMPT inhibition, he believes the company is well positioned to expand into broader areas of the oncology market. 

He shared that he looks forward to working closely with Greg Crimmins, the board, and the entire development team to support the next phase of execution and growth, build long-term value for shareholders, and contribute to bringing meaningful new treatment options to patients with the greatest unmet needs.